RxDoctor Payments Data

Lori Eaton, NP

Adult Health · Matthews, NCNPI 1184916892

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.2% of the total across 532 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 57 manufacturers, the largest accounting for just 17.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $3,288 and has fallen 87.3% since, to $418 in 2025. Among adult health clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$11,025in general payments, 2019–2025

Across 532 payments — averaging $20.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • Pfizer$983
  • AstraZeneca$718
  • Boehringer Ingelheim$525
  • Lilly USA, LLC$444
  • plus $5K from 51 others

What the payments were for

  • Food & beverage$10,94099%
  • Education$851%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie94$1,926
Novo Nordisk77$1,541
Pfizer49$983
AstraZeneca35$718
Boehringer Ingelheim25$525
Lilly USA, LLC23$444
Astellas Pharma US Inc18$406
Johnson & Johnson11$316
GSK9$281
Amgen(2 entities)13$252
Bayer13$234
Takeda Pharmaceuticals U.S.A., Inc.14$227
Esperion Therapeutics, Inc.7$225
Axsome Therapeutics, Inc.5$196
Novartis13$192
Biohaven Pharmaceutical Holding Company Ltd.10$185
Teva Pharmaceuticals USA, Inc.5$170
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC9$165
Sumitomo Pharma America, Inc.8$161
Paratek Pharmaceuticals, Inc.3$153
Xeris Pharmaceuticals, Inc.9$153
Dexcom, Inc.2$129
Abbott5$103
Biohaven Pharmaceuticals, Inc.5$97
Bausch Health US, LLC6$91
IBSA Pharma Inc.5$75
Amarin Pharma, Inc.4$74
Shield Therapeutics Inc4$71
Idorsia Pharmaceuticals US Inc4$64
Insightec,inc1$63
Eisai Inc.4$60
Daiichi Sankyo Inc.3$60
Kowa Pharmaceuticals America, Inc.3$52
Corcept Therapeutics3$51
Merck3$48
Azurity Pharmaceuticals, Inc.2$40
Neos Therapeutics, LP2$40
Sanofi-aventis U.S. LLC2$40
Sunovion Pharmaceuticals Inc.2$35
Inspire Medical Systems, Inc.2$35
Tolmar, Inc.2$33
E.r. Squibb & Sons, L.L.C.2$28
Medtronic2$27
Ironwood Pharmaceuticals, Inc1$24
Hikma Pharmaceuticals USA1$22
Actelion Pharmaceuticals US, Inc.1$20
Renalytix AI, Inc.1$19
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$19
Upsher-smith Laboratories LLC1$18
Edwards Lifesciences1$18
Supernus Pharmaceuticals, Inc.1$18
Phadia US Inc.1$17
Arbor Pharmaceuticals, Inc.1$17
Phathom Pharmaceuticals, Inc.1$17
GRT US Holding, Inc.1$17
Amneal Pharmaceuticals LLC1$16
Organon1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,025 in reported general payments places this provider in the 95th percentile of 614 adult health providers in North Carolina.

See all adult health providers in North Carolina

Medicare billing

Part B allowed, 2024
$26,371
Medicare patients
129
Services billed
463

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin11$12,418
EliquisApixaban12$11,205
Repatha SureclickEvolocumab15$9,488
Olmesartan Medoxomil38$712
Rosuvastatin Calcium63$685
Levothyroxine Sodium45$626
Atorvastatin Calcium69$545
Amlodipine Besylate56$440
Escitalopram Oxalate20$339
Ezetimibe14$244
Zolpidem Tartrate32$227
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav19$196
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst20$192
Tamsulosin Hcl11$191
Metoprolol Succinate17$177

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$525$12,41811 claims
PfizerEliquis$983$11,20512 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$16$62645 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 614 adult health providers in North Carolina.

Other adult health in Matthews

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →